Cytochrome P450 @entity5322 /5 expression as a biomarker of outcome in XXXX .

@entity1 @entity1885 @entity146 @entity39 @entity3478 @entity5322 @entity5 @entity65490 @entity421 @entity982 @entity3
PURPOSE: @entity421 , the most common pediatric primary @entity3478 , is an @entity146 with a tendency for early pulmonary @entity3 . A reliable biomarker to predict clinical outcome at diagnosis has not yet been identified. To date, pathological review of neoadjuvant chemotherapy-induced @entity39 is the most useful determinant of which @entity1 are likely to develop @entity3 . There is a clinical need to identify @entity1 who will benefit from more aggressive preoperative therapy or perhaps require less aggressive chemotherapy. More than 30 @entity1 P450 isoenzymes have been characterized, with at least nine possessing some clinical relevance. One of these, @entity5322 /5 is involved in metabolic activation and detoxification of a wide number of carcinogens and chemotherapeutic agents, including many drugs that are useful in the treatment of @entity421 . MATERIALS AND METHODS: @entity421 tissue microarray blocks containing biopsies from 18 primary @entity5 were used to analyze the expression of P450s 1A1/2, 1B1, 2B6, 2D6, and 3A4/5 by enzyme-linked avidin- @entity1885 complexed immunohistochemistry. The frequencies of expression were 83%, 67%, and 83% for P450s 1A1/2, 1B1, and 3A4/5, respectively. P450s 2B6 and 2D6 were not detectable. RESULTS: These results were extended by developing a fluorescent-based quantitative immunocytochemistry technique to assess the levels of @entity5322 /5 in 18 @entity982 -embedded primary biopsy sections. Expression of @entity65490 was found to be significantly higher in primary biopsies of @entity1 who developed distant @entity3 compared with biopsies from @entity1 with nonmetastatic disease (P = 0.0004). CONCLUSION: High cytochrome P450 @entity5322 /5 expression may predict @entity3 and poor prognosis in @entity421 . Its use as a biomarker of therapeutic response will have implications for the treatment of these @entity5 .
